Enzymatic Resolution of α‐Methyleneparaconic Acids and Evaluation of their Biological Activity

Chakrabarty, Kuheli; Defrenza, Ivana; Denora, Nunzio; Drioli, Sara; Forzato, Cristina; Franco, Massimo; Lentini, Giovanni; Nitti, Patrizia; Pitacco, Giuliana

doi:10.1002/chir.22419

Cited by 4 publications

(1 citation statement)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…)-1] was obtained with high enantioselectivity (98% ee) by kinetic enzymatic resolution of the corresponding racemic methyl ester, as previously described (10).…”

Section: C75: C75 [(+)-(2r3smentioning

confidence: 99%

Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function

et al. 2019

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and the most common liver cancer. It is expected to become the third leading cause of cancer-related deaths in Western Countries by 2030. This alarming trend can be explained with the increasing incidence of metabolic disorders (i.e. obesity, metabolic syndrome and diabetes), in addition to the major known risk factors such as hepatitis C or B viruses, and alcohol consumption. Effective pharmacological approaches for HCC are still unavailable, and the currently approved systemic treatments are unsatisfactory in terms of therapeutic results showing many side effects. Thus, searching for new effective and nontoxic molecules for HCC treatment is of paramount importance. We previously demonstrated that lysophosphatidic acid (LPA) is a central trigger in the pathogenesis of HCC and that lysophosphatidic acid receptor 6 (LPAR6) actively supports HCC tumorigenicity. Here, we screened for novel LPAR6 antagonists and found that two compounds, 4-methylene-2-octyl-5-oxotetra-hydrofuran-3-carboxylic acid (C75) and 9xantenylacetic acid (XAA), efficiently inhibit HCC growth, both in vitro and in vitro, without displaying toxic effects at the effective doses. We further investigated the mechanisms of action of C75 and XAA and found that these compounds determine a G1-phase cell cycle arrest, without inducing apoptosis at the effective doses. Moreover, we found that both compounds act on mitochondrial homeostasis, by increasing mitochondrial biogenesis and reducing mitochondrial membrane potential. Overall, our results show two newly identified LPAR6 antagonists with a concrete potential to be translated into effective and side-effect free molecules for HCC therapy.

show abstract

“…)-1] was obtained with high enantioselectivity (98% ee) by kinetic enzymatic resolution of the corresponding racemic methyl ester, as previously described (10).…”

Section: C75: C75 [(+)-(2r3smentioning

confidence: 99%